Скачать или смотреть Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics Inc. (NASDAQ: GALT) is a clinical-stage biotechnology company focused on developing novel therapies for chronic liver disease and cancer. The Norcross, Georgia-based company's entire clinical focus is on its lead drug candidate, belapectin (GR-MD-02), a complex carbohydrate drug that inhibits galectin-3. This protein plays a critical role in the development of fibrosis and inflammation in a number of diseases.



As of Friday, June 13, 2025, Galectin's stock (GALT) has been trading around $1.35 per share, with a 52-week range of approximately $0.73 to $3.17. The company's market capitalization is approximately $85 million. Recent stock performance has been influenced heavily by clinical trial results, with analyst ratings turning strongly positive following the latest data release.

Lead Program: Belapectin and the NAVIGATE Trial
Galectin's lead development program for belapectin is in Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as NASH, with cirrhosis. This is the most advanced form of the disease, and for which there are currently no approved treatments other than liver transplant. Belapectin has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for this indication.


The company's future hinges on the success of its NAVIGATE Clinical Trial (NCT04365868), a Phase 2b/3 study evaluating belapectin for the prevention of esophageal varices, which are a life-threatening complication of cirrhosis.

In a significant development, Galectin presented detailed results from the NAVIGATE trial at the European Association for the Study of the Liver (EASL) Congress in May 2025. The key findings were:

Positive Primary Endpoint: In the per-protocol patient population, the 2 mg/kg dose of belapectin demonstrated a statistically significant reduction of 49.3% (p=0.04) in the incidence of new esophageal varices at 18 months compared to placebo.
Supportive Secondary Endpoints: The trial also showed that significantly fewer patients treated with belapectin experienced worsening of liver stiffness, a key biomarker for disease progression.
Encouraging Safety Profile: Belapectin was well-tolerated, with adverse event rates comparable to placebo and no drug-related serious adverse events reported in the trial.
While the 4 mg/kg dose did not achieve statistical significance, the positive result for the 2 mg/kg dose provides a clear path forward and a potential first-in-class therapeutic option for this patient population with a high unmet medical need.

Financial Health and Outlook
Galectin Therapeutics is a clinical-stage company with no commercial revenue and its financial position is a key area of focus for investors.

In its financial results for the first quarter of 2025 (ended March 31, 2025), the company reported:

Cash and Cash Equivalents: $7.4 million.
Available Credit: An additional $11 million available under two lines of credit provided by its chairman.
Cash Runway: The company stated it has sufficient cash to fund its currently planned operations and R&D activities through August 2025.
The limited cash runway is a significant near-term challenge. Following the positive NAVIGATE trial data, the company's next steps will likely involve discussions with regulatory authorities about a potential path to approval. Securing additional funding through partnerships, licensing agreements, or equity financing will be critical to continue the development of belapectin and move towards a potential submission for marketing approval. Analyst price targets have been bullish, with some targets set as high as $12.88, reflecting the significant commercial opportunity for belapectin if it successfully navigates the final stages of development and approval.